Rhythm Pharmaceuticals (RYTM) Reports Late-breaking Data from Ph 3 Trials of Setmelanotide in POMC & LEPR Deficiency Obesities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Rhythm Pharmaceuticals (RYTM) Reports Late-breaking Data from Ph 3 Trials of Setmelanotide in POMC & LEPR Deficiency Obesities

Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

November 4, 2019 4:01 PM EST

-- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index -- 

-- Additional safety analyses show no significant increases in heart rate or blood pressure --

-- Two oral presentations delivered today during special research forum; poster presentations scheduled for Thursday --

BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced additional data from its two pivotal Phase 3... More